Regeneron Pharmaceuticals Inc (REGN)
Solvency ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.05 | 0.06 | 0.07 | 0.08 | 0.12 |
| Debt-to-capital ratio | 0.06 | 0.07 | 0.08 | 0.10 | 0.15 |
| Debt-to-equity ratio | 0.07 | 0.08 | 0.09 | 0.11 | 0.18 |
| Financial leverage ratio | 1.29 | 1.27 | 1.29 | 1.36 | 1.56 |
Regeneron Pharmaceuticals Inc has shown a consistent improvement in its solvency ratios over the period from December 31, 2020, to December 31, 2024.
1. Debt-to-assets ratio has decreased from 0.12 in 2020 to 0.05 in 2024, indicating that the company's level of debt in relation to its total assets has decreased significantly, showcasing a more stable financial position.
2. Debt-to-capital ratio has similarly decreased from 0.15 in 2020 to 0.06 in 2024, demonstrating a reduction in the proportion of debt relative to the total capital of the company, which is a positive indication of improved financial health.
3. Debt-to-equity ratio has shown a decline from 0.18 in 2020 to 0.07 in 2024, indicating that the company is relying less on debt financing and more on equity, which can enhance its financial stability and reduce financial risk.
4. The financial leverage ratio has decreased from 1.56 in 2020 to 1.29 in 2024, suggesting that the company has reduced its reliance on debt to finance its operations over the years, which is a positive trend for its long-term financial viability.
Overall, the decreasing trend in these solvency ratios illustrates Regeneron Pharmaceuticals Inc's strengthening financial position and improved ability to meet its financial obligations.
Coverage ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Interest coverage | 72.30 | 58.52 | 82.80 | 163.75 | 67.97 |
The interest coverage ratio for Regeneron Pharmaceuticals Inc has shown a positive trend over the years, indicating the company's ability to meet its interest obligations comfortably. In December 31, 2021, the interest coverage ratio stood at an impressive 163.75, suggesting the company's earnings are sufficient to cover its interest expenses over 163 times. However, there was a slight decline in the ratio to 82.80 in December 31, 2022, which may raise some concerns despite still being at a healthy level. The ratio further decreased to 58.52 by December 31, 2023, indicating a potential need for the company to assess its ability to generate earnings to cover interest payments. Nonetheless, by December 31, 2024, the interest coverage ratio improved to 72.30, showing a positive sign of recovery. Overall, the interest coverage ratio for Regeneron Pharmaceuticals Inc demonstrates solid financial health and the ability to manage its interest expenses efficiently, with fluctuations in recent years warranting close monitoring.